Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target upped by investment analysts at The Goldman Sachs Group from $36.00 to $41.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price suggests a potential downside of 8.54% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Stock Down 3.9 %

Tarsus Pharmaceuticals stock opened at $44.83 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 6.99. The company’s 50-day moving average is $37.84 and its 200 day moving average is $32.53. Tarsus Pharmaceuticals has a 1-year low of $15.60 and a 1-year high of $52.99.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Tarsus Pharmaceuticals by 16.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock worth $6,924,000 after acquiring an additional 29,465 shares in the last quarter. Vanguard Group Inc. increased its holdings in Tarsus Pharmaceuticals by 14.5% in the 1st quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock worth $66,398,000 after acquiring an additional 231,131 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Tarsus Pharmaceuticals during the first quarter worth $12,640,000. Russell Investments Group Ltd. lifted its holdings in Tarsus Pharmaceuticals by 38,907.8% during the first quarter. Russell Investments Group Ltd. now owns 30,036 shares of the company’s stock valued at $1,092,000 after purchasing an additional 29,959 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at about $28,904,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.